Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Glaucoma in perspective

- PMLiVE

Private sector on rise in England’s NHS, says BMJ

One-third of NHS contracts have gone to private providers since healthcare reforms

- PMLiVE

UCB’s $1.53bn generics sale falls through

Advent and Avista Capita back away from bid to acquire Kremers Urban due to unanticipated conflict in timing

- PMLiVE

FDA approves Ipsen drug to treat rare tumours

Green light for Somatuline Depot in cancer of the neuroendocrine system

- PMLiVE

Novartis’ acromegaly therapy cleared by FDA

Signifor LAR shows superior efficiency to older treatments

- PMLiVE

NICE recommends Pradaxa in blood clot indication

Boehringer drug backed to treat and prevent deep vein thrombosis and pulmonary embolism

- PMLiVE

The use of search engines in health

The vast majority of health seekers use search engines as a starting point to gain information on a disease or illness

FlowMetric Diagnostics names president

Amy Williams has over 25 years of experience in life sciences

- PMLiVE

EMA: Lack of evidence for Ebola treatments

Not enough data to draw conclusions on effectiveness of experimental drugs

- PMLiVE

Patent cliff losses set to cost pharma $65bn by 2019

Lilly, AZ and Otsuka to be hit hard, says GlobalData

- PMLiVE

NICE backs Pfizer drug in kidney cancer

Inlyta near end of two-year struggle for recommendation

- PMLiVE

Germany’s IQWiG delivers bad news for Bayer’s Eylea

Says drug provides no additional benefit over Novartis’ rival Lucentis in eye condition

- PMLiVE

Roche and Exelixis file melanoma duo in US

Combination of cobimetinib and Zelboraf improved progression-free survival by 9.9 months

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links